Last reviewed · How we verify
GSK1024805A
GSK1024805A is a lysophosphatidic acid receptor 1 (LPA1) antagonist that blocks LPA-mediated signaling to reduce fibrotic and inflammatory responses.
GSK1024805A is a lysophosphatidic acid receptor 1 (LPA1) antagonist that blocks LPA-mediated signaling to reduce fibrotic and inflammatory responses. Used for Idiopathic pulmonary fibrosis (IPF).
At a glance
| Generic name | GSK1024805A |
|---|---|
| Also known as | Synflorix |
| Sponsor | GlaxoSmithKline |
| Drug class | LPA1 receptor antagonist |
| Target | LPA1 (lysophosphatidic acid receptor 1) |
| Modality | Biologic |
| Therapeutic area | Fibrosis / Immunology |
| Phase | Phase 3 |
Mechanism of action
LPA1 is a G-protein coupled receptor involved in fibrosis, inflammation, and tissue remodeling. By antagonizing LPA1, GSK1024805A inhibits pathological fibrotic signaling cascades. This mechanism is intended to slow or halt progressive fibrotic diseases by reducing myofibroblast activation and extracellular matrix deposition.
Approved indications
- Idiopathic pulmonary fibrosis (IPF)
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1024805A CI brief — competitive landscape report
- GSK1024805A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI